PrEP Descovy Oral denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for prep descovy oral are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Step Therapy Before Descovy for PrEP — and How to Appeal

UnitedHealthcare's step-therapy (fail-first) protocols for PrEP typically require a trial of a lower-cost formulary PrEP drug — commonly a generic tenofovir disoproxil fumarate-based product — before authorizing Descovy (emtricitabine/tenofovir alafenamide). The clinical and legal basis for overriding this step is grounded in demonstrating that the required first-step drug is not clinically appropriate for this specific patient, was previously tried and failed or caused harm, or that a patient-specific factor makes Descovy the medically necessary choice from the outset.

### Why This Is Appealable

Step-therapy protocols are required by federal and most state laws to include an exception process. An exception must be granted when the required step drug is contraindicated, has caused adverse effects, failed therapeutically, or is otherwise clinically inappropriate for the individual. For PrEP specifically, the two tenofovir prodrugs have distinct safety profiles; a prescriber's clinical rationale for one over the other — based on the patient's individual characteristics — is a recognized basis for a step-therapy override.

Additionally, the ACA preventive-services mandate has been interpreted to require coverage of USPSTF Grade A-recommended PrEP without barriers that create effective cost-sharing. A step-therapy requirement that delays access to a clinically indicated PrEP drug may independently conflict with this mandate on plans subject to it.

### Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 (employer plans) or ACA §2719 (individual/marketplace plans), you have the right to a full and fair internal review of the step-therapy denial. File within the deadline on your denial notice.
• External review: After a final internal denial, you may request IRO review within approximately four months under ACA §2719. The IRO evaluates whether the step-therapy protocol, as applied, is consistent with accepted clinical practice.
• Expedited review: If delay would seriously jeopardize your health, request expedited review — typically decided within 72 hours.
• State law protections: Many states have enacted step-therapy reform laws that cap the number of required steps, mandate exception timelines, and require the insurer to approve an exception when certain clinical criteria are met. Check whether your state's law applies to your plan type.

### Documentation to Gather

1. Prescriber letter of medical necessity — the cornerstone of the appeal. Must explain the clinical rationale for Descovy specifically: patient-specific factors (without quoting numeric thresholds), why the step-therapy alternative is clinically inappropriate or insufficient for this patient, and why the prescriber's clinical judgment supports Descovy as the first-line choice. 2. Documentation of any prior trial of the step drug — if the patient has taken a tenofovir disoproxil fumarate-based PrEP product and experienced adverse effects or inadequate adherence, document dates, effects, and discontinuation reason. 3. FDA prescribing labels for both products — to support the clinical distinction argument and any safety-profile difference relevant to this patient. 4. UHC's step-therapy exception criteria — download from UHC's provider portal. Address every listed exception pathway explicitly; do not leave any unaddressed. 5. Applicable guideline organization reference — cite CDC or USPSTF PrEP guidance generically to anchor the prescriber's clinical rationale in accepted practice.

### Criteria-Mapping Structure

Create a table: left column lists each step-therapy exception criterion from UHC's policy; right column provides the specific clinical fact, chart entry, or prescriber statement that satisfies it. This structured format forces item-by-item review and prevents a generic re-denial.

### Next Step

Obtain UHC's current step-therapy exception criteria before drafting the appeal. The prescriber letter must speak directly to those criteria — a generic letter of medical necessity without criterion-specific language is the most common reason step-therapy appeals fail at the internal stage. If the internal appeal is denied, external review is a strong option: an IRO will apply clinical standards, not UHC's internal policy hierarchy.